Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

被引：0
|
作者：
Haakensen, V. [1 ]
Nowak, A. [2 ]
Ellingsen, E. [3 ]
Grundberg, O. [4 ]
Farooqi, S. [1 ]
Mcculloch, T. [5 ]
Cedres, S. [6 ]
Bjaanaes, M. [1 ]
Helland, A. [7 ,8 ]
机构：
[1] Oslo Univ Hosp, Div Canc Med, Oslo, Norway
[2] Univ Western Australia, Natl Ctr Asbestos Related Dis, Crawley, ACT, Australia
[3] Ultimovacs Asa, Oslo, Norway
[4] Karolinska Inst, Stockholm, Sweden
[5] Aalborg Univ Hosp, Aalborg, Denmark
[6] Vall Dhebron Inst Oncol Vhio, Med Oncol, Vall Dhebron Barcelona Hosp Campus, Barcelona, Spain
[7] Univ Oslo, Clin Med, Oslo, Norway
[8] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Immunotherapy; Mesothelioma; clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P24.07
引用
收藏
页码：S380 / S380
页数：1
相关论文
共 50 条
  • [31] Combination of capecitabine and oxaliplatine as 2nd line treatment in patients with advanced colorectal cancer
    Heras, P.
    Hatzopoulos, A.
    Karagiannis, S.
    Kritikos, K.
    ANNALS OF ONCOLOGY, 2007, 18 : VII76 - VII76
  • [32] HLA-ANTIGEN FREQUENCIES IN MALIGNANT-MELANOMA PATIENTS - A 2ND STUDY
    ROVINI, D
    SACCHINI, V
    CODAZZI, V
    VAGLINI, M
    ILLENI, MT
    TUMORI, 1984, 70 (01) : 29 - 33
  • [33] Follow-Up after First-Line Nivolumab Plus Ipilimumab in Patients with Pleural Mesothelioma: A Real-World Dutch Cohort Study (FLORA-Study)
    Douma, L. H.
    Hofman, M. M.
    Zwierenga, F.
    Buma, A. I. G.
    Schouwink, J. H.
    Burgers, J. A.
    Smesseim, I.
    Dumoulin, D. W.
    Aerts, J. G. J. V.
    de Gooijer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S71 - S71
  • [34] Evaluation of flat dosing for nivolumab (NIVO) plus ipilimumab (IPI) in first-line (1L) unresectable malignant pleural mesothelioma (MPM): CheckMate 743 (CM 743)
    Tsao, A. S.
    Baas, P.
    Nowak, A.
    Zalcman, G.
    Fujimoto, N.
    Peters, S.
    Baudelet, C.
    Aanur, P.
    Osawa, M.
    Tendolkar, A.
    Feng, Y.
    Sheng, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1445 - S1445
  • [35] Paired Liquid and Tissues Biopsies to Guide Treatment for Patients That Progress on 2nd Line Osimertinib Treatment
    Van Der Wel, T.
    Jebbink, M.
    Boelens, M. C.
    Steinbusch, L.
    Buikhuisen, W.
    Theelen, W.
    Ruiter, G.
    Burgers, J.
    Baas, P.
    Smit, E.
    Van Den Broek, D.
    Monkhorst, K.
    De Langen, A. J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S906 - S906
  • [36] LIGHT-NING 2nd interim analysis: Early safety of 1L nivolumab plus ipilimumab plus /- chemotherapy for NSCLC in Japan
    Azuma, Koichi
    Imai, Hisao
    Kijima, Takashi
    Kishi, Kazuma
    Saito, Haruhiro
    Yamaguchi, Teppei
    Hayashi, Hidetoshi
    Shiraishi, Yoshimasa
    Fujita, Kohei
    Watanabe, Satoshi
    Kitazono, Satoru
    Fukuhara, Tatsuro
    Hataji, Osamu
    Toi, Yukihiro
    Mizutani, Hideaki
    Hamakawa, Yusuke
    Maemondo, Makoto
    Ohsugi, Tomoyuki
    Suzuki, Keisuke
    Horinouchi, Hidehito
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1393 - S1393
  • [37] Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
    Rui Kitadai
    Tatsunori Shimoi
    Kazuki Sudo
    Emi Noguchi
    Yusuke Nagata
    Ryoichi Sawada
    Atsuo Takashima
    Narikazu Boku
    Kan Yonemori
    BMC Cancer, 21
  • [38] Carboplatin Plus Pemetrexed as First-line Treatment of Patients With Malignant Pleural Mesothelioma: A Phase II Study
    Katirtzoglou, Nikolaos
    Gkiozos, Ioannis
    Makrilia, Nektaria
    Tsaroucha, Emilia
    Rapti, Aggeliki
    Stratakos, Grigorios
    Fountzilas, Georgios
    Syrigos, Konstantinos N.
    CLINICAL LUNG CANCER, 2010, 11 (01) : 30 - 35
  • [39] Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
    Kitadai, Rui
    Shimoi, Tatsunori
    Sudo, Kazuki
    Noguchi, Emi
    Nagata, Yusuke
    Sawada, Ryoichi
    Takashima, Atsuo
    Boku, Narikazu
    Yonemori, Kan
    BMC CANCER, 2021, 21 (01)
  • [40] Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.
    Gordon, Erlinda Maria
    Chua-Alcala, Victoria S.
    Kim, Katherine
    Andrali, Shiva Sreenath
    Del Rosario, Marie
    Tseng, William W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345